Greenwich LifeSciences (GLSI) vs MacroGenics (MGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MacroGenics (MGNX) has outperformed Greenwich LifeSciences (GLSI) over the past year, gaining 106.4% versus a gain of 37.0%. Over five years, GLSI leads with a -59.5% price change compared with -82.0% for MGNX. MacroGenics is the larger company by market cap ($227.1 million vs $217.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | MGNX |
|---|---|---|
| Share price | $14.80 | $3.57 |
| Market cap | $217.24M | $227.09M |
| 1-day change | -3.83% | +0.42% |
| YTD return | -26.75% | +120.50% |
| 1-year return | +37.04% | +106.40% |
| 5-year return | -59.46% | -82.02% |
| EPS (TTM) | $-1.53 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $5.08 |
| 52-week low | $7.78 | $1.29 |
| Distance from 52-week high | -56.60% | -29.82% |
| Analyst consensus | none | buy |
| Avg. price target upside | +285.14% | +124.40% |
| Average volume | 138.72K | 621.73K |
| Shares outstanding | 14.68M | 63.70M |
| Employees | — | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed GLSI by 69.4 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
GLSI vs MGNX FAQ
Which is bigger, Greenwich LifeSciences or MacroGenics?
MacroGenics (MGNX) is larger, with a market capitalization of $227.09M compared with $217.24M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or MGNX?
MGNX returned +106.40% over the past 12 months, compared with +37.04% for GLSI (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and MacroGenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.